Basic Information
| LncRNA/CircRNA Name | LINC00520 |
| Synonyms | NA |
| Region | GRCh38_14:55781135-55796688 |
| Ensemble | ENSG00000258791 |
| Refseq | NR_026796 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | papillary thyroid cancer |
| ICD-0-3 | NA |
| Methods | RT-qPCR, Western blot |
| Sample | PTC tissues,cell lines (HTH83, K-1, BCPAP, and TPC-1) |
| Expression Pattern | up-regulated |
| Function Description | LINC00520 functioned as an oncogenic lncRNA in PTC, and it facilitated PTC progression by regulating the miR-577/Sphk2 axis, suggesting that the LINC00520/miR-577/Sphk2 axis is an effective target in anticancer management. |
| Pubmed ID | 32075502 |
| Year | 2020 |
| Title | Long noncoding RNA LINC00520 accelerates progression of papillary thyroid carcinoma by serving as a competing endogenous RNA of microRNA-577 to increase Sphk2 expression |
External Links
| Links for LINC00520 | GenBank HGNC NONCODE |
| Links for papillary thyroid cancer | OMIM COSMIC |